DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation
JCI Insight · 23.03.2026 · 11 (6)
DOI: 10.1172/jci.insight.200054 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 23.03.2026. Verfasst von Celine Bruge und 16 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Université d'Evry, Inserm, IStem, UMR861, Corbeil-Essonnes, France. Hauptthemen laut MEDLINE: Lipid Metabolism, Muscular Dystrophies, Limb-Girdle, Adaptor Proteins, Vesicular Transport, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Laboratoire d’Excellence Revive, The Genopole Biocluster, BPI France.
Abstract (Originalsprache)
Limb-girdle muscular dystrophy R2 (LGMD R2) is an autosomal recessive disorder caused by dysferlin deficiency, leading to progressive muscle weakness and wasting. The lack of reliable clinical biomarkers has limited disease monitoring and therapeutic evaluation. Here, we identified Disabled-2 (DAB2) as a molecular and clinical indicator of disease state in LGMD R2. Transcriptomic profiling revealed a significant upregulation of DAB2 in induced pluripotent stem cell–derived (iPSC-derived) myotubes from patients, a finding validated in muscle biopsies from 14 dysferlin-deficient individuals and in dysferlin-deficient Bla/J mice, where DAB2 levels increased with disease progression. Importantly, AAV-mediated expression of full-length dysferlin restored DAB2 levels, supporting its value as a dynamic readout of disease activity for both disease monitoring and therapeutic response. Given the established role of DAB2 in clathrin-mediated endocytosis, particularly in LDL receptor internalization and cholesterol homeostasis, and the pathological lipid accumulation reported in LGMD R2, we investigated its contribution to lipid dysregulation. High DAB2 expression paralleled lipid deposition in patient muscles, iPSC-derived myotubes, and mouse tissue, whereas siRNA-mediated DAB2 knockdown reduced lipid accumulation in LGMD R2 myotubes. Collectively, these findings suggest that DAB2 functions as a mechanistic link between dysferlin deficiency, altered lipid handling, and disease severity, and they highlight its potential as a prognostic marker and therapeutic response measure for LGMD R2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris-Saclay, Université d'Evry, Inserm, IStem, UMR861, Corbeil-Essonnes, France.
- IStem, CECS, Corbeil-Essonnes, France.
- INTEGRARE, Genethon, Inserm, Université d'Evry, Université Paris-Saclay, Evry, France.
- Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.
- Unité de Morphologie Neuromusculaire, Institut de Myologie, Sorbonne université, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
- Centre de Référence des maladies Neuromusculaires Nord/Est/Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, APHP, Paris, France.
Förderung
- Laboratoire d’Excellence Revive
- The Genopole Biocluster
- BPI France
- the Rare Diseases Foundation
- Association Française contre les Myopathies
- Region Ile de France
- European Union
- Université Paris-Saclay
Zitieren
APA
Bruge, C., Bourg, N., Pellier, E., Miagoux, Q., Benabides, M., Grossi, N., Hayat, H., Jarrige, M., Polveche, H., Agostini, V., Brureau, A., Vassilopoulos, S., Evangelista, T., Fernández-Eulate, G., Stojkovic, T., Richard, I., & Nissan, X. (2026). DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation. JCI Insight, 11(6). https://doi.org/10.1172/jci.insight.200054
Vancouver
Bruge C, Bourg N, Pellier E, Miagoux Q, Benabides M, Grossi N, et al. DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation. JCI Insight. 2026;11(6). doi:10.1172/jci.insight.200054
BibTeX
@article{Bruge2026,
author = {Bruge, Celine and Bourg, Nathalie and Pellier, Emilie and Miagoux, Quentin and Benabides, Manon and Grossi, Noella and Hayat, Hassan and Jarrige, Margot and Polveche, Helene and Agostini, Valeria and Brureau, Anthony and Vassilopoulos, Stephane and Evangelista, Teresinha and Fernández-Eulate, Gorka and Stojkovic, Tanya and Richard, Isabelle and Nissan, Xavier},
title = {DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {6},
doi = {10.1172/jci.insight.200054}
}
EUVIMED